The hepatic tumorigenicity of CI-924 (5,5'-(1,1'-biphenyl)-2,5-diylbis(oxy)(2,2-dimethylpentanoic acid)), a hypolipidemic agent, was evaluated in 50 B6C3F1 mice/sex/dose given drug in the diet at 0, 5, 25, and 75 mg/kg/day for 2 yr. Peroxisomal and drugmetabolizing enzyme determinations, as well as ultrastructural evaluations, were conducted in subsets of these same groups, because drugs of this class cause peroxisome proliferation and hepatic tumors in rodents. CI-924 elicited dose-dependent increases in the incidence of hepatocellular adenomas and carcinomas in both sexes that were statistically significant at 75 mg/kg. Stereologic evaluation revealed significant increases in hepatocellular peroxisome volume ratio, due to increased numbers of peroxisomes, in females at all doses and males at 75 mg/kg. Peroxisomal enzyme activity measurements revealed no change in catalase, but dose-dependent increases in carnitine acetyltransferase and cyanide-insensitive &beta;-oxidation in both sexes. Peroxisome proliferation, determined biochemically or ultrastructurally, was twice as great in females compared to males. Total cytochrome P-450 was increased in both sexes given 75 mg/kg. There were dose-dependent decreases in glutathione S-transferase in males and increased glutathione peroxidase in both sexes at 25 and 75 mg/kg. In conclusion, this study demonstrated that while CI-924 induced hepatic tumors in male and female B6C3F1 mice the associated peroxisome proliferation, while moderate in females, was only weak in the males after 2 yr of exposure.
INTRODUCTION
The hypolipidemic agent (5, 5 '-( 1,1'-biphenyl)-2,5-diylbis(oxy)(2,2-dimethylpentanoic acid)) ( Fig. 1) is a pentanoic acid with structural similarities to the fibriq acid drug group (31) . In preclinical pharmacologic studies, CI-924 was shown to be more potent than gemfibrozil with respect to lowering low-density lipoprotein (LDL) cholesterol concentrations while concomitantly elevating high-density lipoprotein (HDL) cholesterol levels in male CD rats given a high-fat diet (31) . In human clinical trials, CI-924 was effective in elevating HDL in patients with Type II or Type IV hyperlipoproteinemia (7) . Triglycerides were lowered in Type IV patients whereas cholesterol and LDL/HDL were lowered in Type II patients (7) .
Derivatives of fibric acids are generally not mutagenic or clastogenic but in short-term studies in rodents cause hepatic peroxisome proliferation that is usually associated with hepatic tumor induction in long-term studies (1, 32) .
Previous toxicologic evaluations showed that CI-924 was not mutagenic (25) but elicited dose-dependent increases in hepatic peroxisome volume fraction, due to increased numbers and size of peroxisomes, in male CDF rats given 5 and 25 mg/kg in a high-lipid diet for 4 wk (26) . Subsequent studies demonstrated dose-dependent increases in peroxisomal enzyme activities in B6C3F1 mice and Wistar rats given doses of 25-150 mg/kg/day for 4 wk (15, 16) . However, was not hepatotumorigenic in Wistar rats given up to 30 mg/kg/day in the diet for 2 yr (12) . We report here the results of hepatic tumor evaluations in groups of 50 B6C3F1 mice/sex/dose group given CI-924 for 2 yr, as well as hepatic peroxisomal and drugmetabolizing enzyme analyses and ultrastructural stereologic evaluations in both male and female mice after 2 yr of CI-924 administration on subsets of the same groups that were used for the tumor evaluation. (6) and carnitine acetyltransferase (4, 17) activities. The remaining 700 X g supernatant was centrifuged for 15 min at 10,000 X g, and the resulting pellet was resuspended in 0.25 M sucrose for analysis of cyanide insensitive (3-oxidation (21) . The 10,000 X g supernatant was used directly for analysis of glutathione Stransferase (13) and glutathione peroxidase (30) activities and for the preparation of microsomes by precipitation with calcium chloride (18) . Microsomes were resuspended in 0.1 M phosphate buffer (pH 7.4) for determination of total cytochrome P-450 concentration (29) , cytochrome c reductase activity (24) , and protein concentration (27 uranyl acetate and lead citrate, and centrilobular/midzonal regions were photographed at X7,000 magnification on a Philips CM-10 electron microscope using the &dquo;specimen XY control program&dquo; at low magnification to minimize bias and avoid potential redundancy in the selection of sites for photography. Electron micrographs from all animals were analyzed using a Summagraphics digitizing tablet and Java software program for peroxisomal number and area. Electron micrographs from all high-dose and control females were also analyzed for mitochondrial number and area and smooth and rough endoplasmic reticulum using intercepts with a grid of test lines and the location of their end points (37) . Stereologic variables were calculated using standard formulas (37 (Table I ).
MATERIALS AND METHODS
In animals euthanatized after 2 yr of CI-924 administration, the difference from controls was statistically significant at the high dose (75 mg/kg) for adenomas in males and females, carcinomas in males, and adenomas and/or carcinomas in both sexes. When animals that died or were euthanatized in moribund condition before the end of study were added to those necropsied after 2 yr, the incidence pattern was similar. In general, the incidence of adenomas dropped slightly while that of carcinomas increased, reflecting the relatively higher incidence of carcinomas in animals that died or were euthanatized in moribund condition before the completion of 2 yr of dosing. The higher incidence of carcinomas in middose males (25 mg/kg), compared to controls, became statistically significant when all animals were included, reflecting the higher incidence of carcinomas in animals that died or were euthanatized in moribund condition and the slightly higher mortality in this group. CI-924 treatment was not associated with any other hepatic changes. This evaluation included the foci of cellular alteration, which were of similar low incidence ( 1-5 mice/sex/group), size, and morphology in the control and CI-924-treated animals.
Dose-dependent and statistically significant increases in absolute and relative liver weight occurred in the males at all dose levels (Table II) . In females, absolute and relative liver weight was significantly increased only at the high dose. It should be noted, however, that liver weights included the tumors that probably contributed, in part, to the effects on liver weight. Stereologic evaluation revealed a tendency toward dose-dependent increases in hepatocellular volume in both sexes; however, the difference from controls was statistically significant only for the high-dose males (Table II) .
There were statistically significant increases in hepatic microsomal total cytochrome P-450 concentration in males and females given 75 mg/kg, compared to controls (Fig. 2) , but no significant changes in cytochrome c reductase activity (data not shown). In the 10,000 X g liver supernatants, there were dose-dependent decreases in glutathione S-transferase activity of males at all dose levels, but no decreases in females, and increases in glutathione peroxidase activity that achieved statistical significance in males and females given 25 and 75 mg/kg (Fig. 2) . Analyses of the 700 X g liver supernatants revealed slight decreases in the catalase activity of females given 25 or 75 mg/kg, compared to controls, but no changes in the catalase activity of males. In addition, there were dosedependent increases in carnitine acetyltransferase activity that were statistically significant at 25 and 75 mg/kg in males and at all dose levels in females (Fig. 3 ). There were statistically significant increases in cyanide-insensitive (3-oxidation in males and females given 25 and 75 I mg/kg compared to controls (Fig. 3) . z Electron microscopic evaluation clearly showed increased numbers of peroxisomes in hepatocytes, particularly in the high-dose females, compared to controls (Fig. 4) . Many peroxisomes in both CI-924 and control animals contained an electron-dense crystalloid core or nucleoid. In females, morphometric and stereologic evaluations revealed dose-dependent increases in hepatocellular peroxisomal volume ratio, the number of peroxisomes per hepatocyte, and peroxisomal volume per hepatocyte, which were statistically significant at all dose levels compared to controls (Fig. 5) . In males, peroxi- (1, 28, 32) . However, in contrast to the majority of studies in which peroxisome proliferation has been determined after short-term administration (and correlated to hepatotumorigenicity in long-term bioassays), peroxisome proliferation in the present study was measured after 2 yr of drug administration on subsets of the same animal groups that were used for CI-924 tumor evaluation.
Peroxisome proliferation, determined morphologically or from increased carnitine acetyltransferase and ~3-oxidation activities, in the female mice was approximately twice that of males given the same administered mg/kg dose level. Indeed, there was good agreement between the morphologic and biochemical methods of measuring peroxisome proliferation. The low potency of CI-924 with respect to peroxisome proliferation in the male mice was unexpected in view of the positive tumorigenic response in both sexes but may be an age-related phenomenon. Peroxisome proliferation in 2-mo-old B6C3F1 mice given CI-924 for 4 wk at the same dose levels did not reveal significant differences between males and females, and the magnitude of the increases in both sexes, relative to their concurrent controls, was similar to that of females given CI-924 for 2 yr (15, 16) .
Administration of the leukotriene D4-antagonist LY171883 to B6C3F1 mice also elicited hepatic tumors in both sexes and was associated with little more than a doubling in peroxisomal [3- oxidation in both males and females after 2 yr of administration (3) . Furthermore, age susceptibility of peroxisome proliferation was evident in the decreased induction of peroxisomal (3-oxidation by the hypolipidemic drug clofibrate in male Fischer-344 rats from 52 to 117 wk (38) . The aryloxyphenoxy herbicide haloxyfop is another compound considered a peroxisome proliferator that elicited only weak peroxisome proliferation activity in a 2-4-wk study at the dose level causing hepatic tumors in female B6C3F1 mice in a longterm study (33) . However, as also noted by the latter authors, these findings are still consistent with the concept that peroxisome proliferation represents a potential mark-er for tumorigenic activity, at least at some dosage, in rodents.
The increase in cytochrome P-450 concentration at the high dose in both sexes is probably due, at least in large part, to induction of the CYP4A isoenzyme. Induction of CYP4A by CI-924, determined from increases in lauric acid hydroxylase activity and immunoblotting, has been demonstrated in 4-wk studies of CI-924 in mice and rats (15, 16) . Induction of CYP4A isoenzymes is characteristic of this class of compounds and also appears to be mediated by activation of PPAR (10, 11, 20) . There was no CI-924-induced proliferation of smooth endoplasmic reticulum, or indeed of mitochondria, that has been reported for other hypolipidemic peroxisome proliferators (14) .
The mechanism by which peroxisome proliferators cause hepatocellular tumors is not clearly understood; however, one hypothesis that has been a useful framework for study has suggested that the proliferated peroxisomes are essential for tumorigenesis due to the much greater and sustained induction of H202-producing enzymes, such as those of peroxisomal (3- (19) . Consistent with this hypothesis, catalase activity was unchanged in CI-924-treated animals whereas peroxisomal (3-oxidation was significantly increased, as noted earlier. The absence of an effect on catalase activity is consistent with other peroxisome proliferators where increases in catalase activity are proportionally much less than the increases in the activities of other enzymatic markers such as carnitine acetyltransferase and (3-oxidation (32) .
Also potentially contributing to oxidative stress induced by peroxisome proliferators are reported decreases in glutathione S-transferase and glutathione peroxidase activities (19) . However, in the present study with CI-924, glutathione S-transferase decreased in males only and glutathione peroxidase was relatively unaffected. This pattern was generally similar to that seen in B6C3F1 l mice given CI-924 for 4 wk in which, compared to controls, glutathione S-transferase activity was decreased in males given 75 or 150 mg/kg but remained unchanged in females, whereas glutathione peroxidase activity increased slightly in females given 25 mg/kg and higher doses but remained unaltered in males (15, 16) . These results are consistent with the published literature, which generally indicates that peroxisome proliferators usually, but not always, inhibit glutathione peroxidase activity (5) and do not have consistent effects on glutathione S-transferase in mice (8) .
More recently, it has been suggested that other risk factors probably influence the relative hepatotumorigenicity of peroxisome proliferators (34) . Among these is a role for systemic toxicity, as manifested by phenomena such as significant decreases in body weight at tumorigenic doses. The latter has been suggested as an explanation for significant Wy-14,643-induced peroxisome proliferation and hepatocellular replication at doses much less than those shown to be tumorigenic (34) . However, CI-924 was well tolerated clinically by mice at the tumorigenic dose of 75 mg/kg, as determined by the absence of body weight and food consumption changes, in both the current 2-yr study and a previous 4-wk study (16) .
Alternative mechanisms proposed to explain hepatotumorigenicity induced by peroxisome proliferators include enhanced cell replication, particularly where sustained, and promotion of spontaneous preneoplastic lesions (20, 34) . The CI-924-induced increases in liver weight and hepatocyte volume are consistent with other hypolipidemic peroxisome proliferators and attributed to hypertrophy and hyperplasia, the latter phenomenon reflecting enhanced cell replication (19, 20, 28) .
In conclusion, administration of the hypolipidemic agent CI-924 to B6C3F mice for 2 yr caused peroxisome proliferation, which was twice as great in females compared to males, and an increased incidence of hepatocellular tumors in both sexes. The lower potency of CI-924 with respect to peroxisome proliferation in the males was unexpected in view of the positive tumorigenic response ; however, relatively greater peroxisome proliferation, based on comparison to concurrent controls, was seen in males given CI-924 in a previous 4-wk study. The reasons why peroxisome proliferation was not sustained at higher levels in the males, as it was in the females, is unknown at this time.
